Millipore’s goal is to gain insight into current and future needs for safety and toxicity testing applications in pre-clinical drug discovery.

How Millipore will contribute to the DSEC community: Millipore will bring knowledge, capabilities and the commitment to develop products and services that will help advance successful discovery safety and toxicity testing.  Our goal is to develop solutions that change safety and toxicity testing from a predominantly observational practice to a more predictive discipline.

Capability Overview: At Millipore, we understand our customers’ work and share their commitment to bioscience research and biopharmaceutical manufacturing. Our experts provide informed advice from a peer perspective at all stages of our customers’ processes. Our broad range of Life Science tools, technologies, and services make it possible for us to create personalized solutions to industry challenges and assure scientific success.

Subject Matter Experts:   Dr. Jeff Clare, Ph.D., R&D Director.  Dr. Clare is principally responsible for the R&D of the ion channel program with oversight of other cell-based assay research and development projects.

Dr. David Hayes, Ph.D., R&D Director.  Dr. Hayes is principally responsible for the research and development of multiplex assays using the Luminex platform and for the evaluation of new assay and platform technology.

Dr. Andrew Ball, Ph.D., Senior Scientist.  Dr. Ball is the group leader for the development of in vitro toxicity assays using high content imaging platforms.

Website: www.millipore.com

Current Article: Dr. Andrew Ball, Senior Scientist, co-authored an article entitled A Neuronal and Astrocyte Co-Culture Assay for the High-Content Analysis of Neurotoxicity. If you would like a copy, please provide your email address below.

Email address: